Abbott Reports Third-Quarter 2013 Results - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Abbott Reports Third-Quarter 2013 Results


Abbott’s third-quarter 2013 results show that worldwide reported sales increased 2%, including an unfavorable 2.3% effect of foreign exchange, the company announced in a press release. A sales disruption in Abbott’s International Nutrition business, caused by a supplier recall in early August 2013 in certain international markets of pediatric nutrition products, is estimated to have reduced Abbott's total worldwide sales growth by nearly 2%. Abbott confirmed its full-year 2013 ongoing EPS guidance range of $1.98–2.04.

The company’s Established Pharmaceuticals business segment sales increased 0.6% in the third quarter on an operational basis and decreased 2.9% on a reported basis, including an unfavorable 3.5% effect of foreign exchange. In key emerging markets, reported sales decreased 3.4%, including an unfavorable 5.7% effect of foreign exchange. Abbott is focused on implementing tailored strategies to drive accelerated growth across its key emerging markets. While recent macroeconomic and market pressures in certain emerging markets resulted in somewhat slower sales growth this quarter, growth rates in emerging markets have and are expected to continue to outpace the overall global economy and remain attractive over the long term, the company said in the press release. Other markets include developed markets, such as Western Europe and Japan, and other emerging markets globally. Sales in these geographies decreased 0.9% in the quarter on an operational basis and 2.4% on a reported basis, including an unfavorable 1.5% effect of foreign exchange.

Source: Abbott

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
32%
Breakthrough designations
11%
Protecting the supply chain
37%
Expedited reviews of drug submissions
11%
More stakeholder involvement
11%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests

Click here